Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

NCT ID: NCT03920631

Last Updated: 2021-03-23

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-10
• Study Completion Date: 2023-05-15

Brief Summary

The purpose of this study is to find out if microtransplantation (MST) in combination with nivolumab is safe and effective in patients with relapsed or refractory B cell lymphomas.

Detailed Description

This is a non-randomized, open-label, phase 1 study to assess the safety of nivolumab (OPDIVO™, also referred to as BMS-936558, MDX1106, and ONO-4538) in combination with microtransplantation (MST) in patients ≥ 18 years of age with relapsed or refractory B cell lymphomas. A conventional cohorts-of-3 dose-escalation phase I design will be used to determine the optimal dosing strategy of nivolumab in combination with MST. The safety of microtransplantation without nivolumab will be evaluated at the first dose level. If significant, unexpected toxicity is observed at Dose Levels 2 or 3, subsequent cohorts will switch to the alternate dosing schedule to evaluate the safety of dose-reduced nivolumab. After determination of the maximum tolerated dose level, patients will be recruited into an expansion cohort at that level.

Conditions

B Cell Lymphomas

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1: Microtransplantation (MST)

MST:Infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)

Group Type: EXPERIMENTAL

Microtransplantation

Intervention Type: BIOLOGICAL

HLA-mismatched peripheral blood stem cells

Cohort 2/2b: MST + Nivolumab

2: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day+14)

2b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day+14).

Group Type: EXPERIMENTAL

Nivolumab

Intervention Type: DRUG

Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

Microtransplantation

Intervention Type: BIOLOGICAL

HLA-mismatched peripheral blood stem cells

Cohort 3/3b: MST + Nivolumab

3: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day-1).

3b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day-1).

Group Type: EXPERIMENTAL

Nivolumab

Intervention Type: DRUG

Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

Microtransplantation

Intervention Type: BIOLOGICAL

HLA-mismatched peripheral blood stem cells

Cohort 4: Expansion

Microtransplantation (Day 0) + nivolumab (at RP2D)

Group Type: EXPERIMENTAL

Nivolumab

Intervention Type: DRUG

Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

Microtransplantation

Intervention Type: BIOLOGICAL

HLA-mismatched peripheral blood stem cells

Interventions

Nivolumab

Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

Intervention Type: DRUG

Microtransplantation

HLA-mismatched peripheral blood stem cells

Intervention Type: BIOLOGICAL

Other Intervention Names

OPDIVO™, BMS-936558, MDX1106, ONO-4538

Eligibility Criteria

Inclusion Criteria

1. Patients with relapsed/refractory B cell lymphomas of the following subtypes:

• Diffuse large B-cell lymphoma (DLBCL)
• High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations (DHL/THL)
• B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (GZL)
• Primary mediastinal large B-cell lymphoma (PMBCL)
• Mantle cell lymphoma (MCL)
• Follicular lymphoma (FL)
• Marginal zone lymphoma (MZL)
• Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM)
• Hodgkin lymphoma (HL)

2. Ability to provide written informed consent for the protocol and understand the investigational nature of the study.

3. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other procedures.

4. Age ≥ 18 years old.

5. Eastern Cooperative Oncology Group performance status of ≤ 2.

6. Evidence of at least one measurable lesion on imaging, defined as nodes/nodal masses > 1.5 cm, extranodal masses >1.0 cm or PET avid lesions consistent with lymphoma.

7. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, and men who are sexually active must use effective methods of contraception from the time of enrollment to 1 month after last therapy administered as part of the protocol.

8. Must have biopsy-proven primary refractory disease or relapsed disease after frontline therapy.

9. Adequate organ function parameters:

1. Renal function: Creatinine clearance ≥ 45ml/min (Cockrauft-Gault Formula)

2. Liver function:

• AST/ALT ≤ 3x the institutional ULN.
• Total bilirubin ≤ 2x the institutional ULN with the exception of patients with Gilbert syndrome; patients with Gilbert syndrome may be included if their total bilirubin is ≤ 3.0x ULN and direct bilirubin is ≤ 2x ULN

3. Pulmonary function: PFTs with DLCO ≥ 40%.

4. Cardiac function: Must have LVEF ≥ 40% confirmed by echocardiogram or MUGA scan.

5. Bone marrow reserve without transfusion defined as:

• Absolute neutrophil count (ANC) ≥ 1,000/mm3
• Platelets ≥ 50,000/mm3

10. Subjects must have a potential 3-5/6 HLA-matched (A, B, DRB1) related haploidentical donor (either a first or second- degree relative) that will be evaluated for eligibility to provide hematopoietic cells for infusion.

Exclusion Criteria

1. Prior Treatments:

1. Prior treatment with allogeneic HSCT.

2. Treatment with CAR-T cells within 6 months of study enrollment.

3. Treatment with an immune checkpoint inhibitor within 3 months of study enrollment.

4. Prior grade 3 or higher toxicities with immune checkpoint inhibitor use, excluding lymphopenia, asymptomatic amylase or lipase elevation or laboratory abnormalities that correct to grade 1 within 72 hours.

5. Chemotherapy, radiation or surgical resection of malignancy within 2 weeks prior to the start of lymphodepleting chemotherapy (washout period).

2. Active, uncontrolled serious infection or medical or psychiatric illness, that in the investigator's opinion is likely to interfere with participation in this clinical trial.

3. Known active CNS involvement by malignancy.

4. History of seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.

5. Active replication of hepatitis B or active hepatitis C (HCV RNA positive). Those with prior disease who are PCR negative at enrollment and meet liver function eligibility criterion are eligible.

6. Known HIV positive patients.

7. Patients with unstable angina and/or myocardial infarction within 6 months prior to screening.

8. Cardiac arrhythmia not controlled with medical management, evidence of pericardial effusion on imaging that is compromising function.

9. History of a second malignancy requiring treatment at any time within the 3 years prior to study enrollment. The following are allowed within 3 years of study enrollment if subject has received definitive local therapy (i.e., surgical excision, external beam radiation, or other local therapy with curative intent): non-melanoma skin cancers, organ-confined localized prostate cancer treated with curative intent, or carcinoma in situ.

10. Active autoimmune disease, history of primary immunodeficiency, or any syndrome that requires systemic corticosteroids or immunosuppressive medications (excluding Hashimoto's thyroiditis, vitiligo, or DM type I).

11. History of solid organ transplantation.

12. Pregnant or lactating women.

13. Prisoners or those compulsorily detained.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ahmed Galal, MD

OTHER

Sponsor Role: lead

Responsible Party

Ahmed Galal, MD

Instructor in the Department of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Ahmed Galal, MD

Role: PRINCIPAL_INVESTIGATOR

Duke Health

Locations

Duke University

Durham, North Carolina, United States

Countries

United States

Other Identifiers

Pro00101349

Identifier Type: -

Identifier Source: org_study_id